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 53 
ABSTRACT (249/250) 54 
A newly recognized pneumococcal serotype 35D, which differs from the 35B polysaccharide 55 
in structure and serology by not binding to factor serum 35a, was recently reported. The 56 
genetic basis for this distinctive serology is due to the presence of an inactivating mutation in 57 
wciG, which encodes an O-acetyltransferase responsible for O-acetylation of a 58 
galactofuranose.  Here, we assessed the genomic data of a worldwide pneumococcal 59 
collection to identify serotype 35D isolates and understand their geographical distribution, 60 
genetic background and invasiveness potential. Of 21,980 pneumococcal isolates, 444 were 61 
originally typed as serotype 35B by PneumoCaT. Analysis of wciG revealed 23 isolates from 62 
carriage (n=4) and disease (n=19) with partial or complete loss-of-funtion mutations, 63 
including mutations resulting in pre-mature stop codons (n=22) and an in-frame mutation 64 
(n=1). These were selected for further analysis. The putative 35D isolates were 65 
geographically widespread and 65.2% (15/23) of them was recovered after PCV13 66 
introduction. Compared with serotype 35B, putative serotype 35D isolates have higher 67 
invasive disease potentials based on odds ratio (OR) (11.58; 95% CI, 1.42-94.19 vs 0.61; 68 
95% CI, 0.40-0.92) and a higher prevalence of macrolide resistance mediated by mefA 69 
(26.1% vs 7.6%, p=0.009). Using Quellung, 50% (10/20) of viable isolates were serotype 70 
35D, 25% (5/20) serotype 35B, and 25% (5/20) a mixture of 35B/35D. The discrepancy 71 
between phenotype and genotype requires further investigation. These findings illustrated a 72 
global distribution of an invasive serotype 35D among young children post-PCV13 73 
introduction and underlined the invasive potential conferred by the loss of O-acetylation in 74 
the pneumococcal capsule.  75 
 76 
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 78 
 79 
INTRODUCTION 80 
Streptococcus pneumoniae (pneumococcus) is an important human pathogen that 81 
causes pneumonia, bacteremia, and meningitis. In 2015, >330,000 deaths globally in children 82 
<5 years old were estimated to have been caused by pneumococci (1). Its polysaccharide 83 
capsule, which has almost 100 serological variants (serotypes), is a major virulence factor (2, 84 
3). Pneumococcal conjugate vaccines (PCVs) targeting up to 13 serotypes have gradually 85 
been introduced into 139 countries since the early 2000s (http://view-hub.org/viz/).  86 
Simultaneously, a proportional increase in non-vaccine serotypes, such as serotype 35B, has 87 
been reported in various countries (4).   88 
Recently, a serotype 35B variant, 35D, was identified in four pneumococcal isolates 89 
in Australia (5) and two in the USA (2, 6). All of which had an inactivating mutation in wciG, 90 
which encodes an O-acetyltransferase responsible for O-acetylation of a galactofuranose. 91 
Nuclear magnetic resonance (NMR) analysis on a single isolate representing this novel 92 
pneumococcal serotype verified that the serotype 35D capsule lacked O-acetylation but was 93 
otherwise identical to serotype 35B (2). Serologically, it is distinct from serotype 35B strain 94 
by consistently not binding to factor serum 35a but it displays variable reactivity to group 35 95 
antiserum (2, 5, 6). WciG functionality has been shown to be the determinant of factor serum 96 
35a recognition (2, 7). 97 
Presence and absence of O-acetylation is one of the mechanisms for generating 98 
diversity in capsular structure as shown by other serotype pairs such as 9V/9A (O-acetylation 99 
mediated by WciE) (8), 11A/11E (WcjE) (8), 15B/15C (WciZ) (8), 33A/33F (WcjE) (9), and 100 
35C/42 (WciG) (7). It is noteworthy that the O-acetyl group in the capsular repeat unit is 101 
important for innate immune recognition (10) and is the target of vaccine-elicited antibodies 102 
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(11). Loss of O-acetylation in serotype 11E is predicted to assist pneumococci in evading 103 
host immune and vaccine response, and has been suggested to occur during invasive disease 104 
after initial colonization with the serotype 11A strain expressing an O-acetylated form of 105 
capsule (12). The role of loss of O-acetylation in pneumococcal survival during invasion 106 
among the other serotype pairs has remained unknown due to the rarity of serotype 9A, 33A, 107 
and 42 for comparisons, and the difficulty in differentiation between serotype 15B and 15C.  108 
Although the serological profile and biochemical structure of serotype 35D have been 109 
described, there has not been an opportunity to comprehensively study this serotype across 110 
geographies and clinical considerations. Here, we assessed the genomic data on serotype 35D 111 
isolates from a worldwide pneumococcal collection to understand its geographical 112 
distribution, genetic background and potential invasiveness.  113 
 114 
RESULTS AND DISCUSSION 115 
Of 21,980 assembled pneumococcal genomes from the Global Pneumococcal 116 
Sequencing (GPS) project (n=16,575, May 2017) and a compiled dataset (n=5,405) by Van 117 
Tonder et al. (13), 444 isolates from disease (n=173), carriage (n=270), and unknown source 118 
(n=1) were originally typed as serotype 35B by PneumoCaT (5). The wciG alignment 119 
revealed that 78.6% (349/444) of isolates were identical to the serotype 35B reference, 8.3% 120 
(37/444) had silent mutations, 7.9% (35/444) had missense mutations, 3.4% (15/444) had 121 
frameshift mutations, 1.6% (7/444) had non-sense mutations, and 0.2% (1/444) had an in-122 
frame insertion. All frameshift mutations led to a pre-mature stop codon which disrupted the 123 
coding region of wciG. Given that the latter three types of mutations lead to reduced function 124 
or a complete loss of function of WciG, the 23 isolates were designated serotype 35D (Table 125 
1). The Quellung reaction of 20 viable isolates showed that 50% (10/20) were serologically 126 
typed as serotype 35D, 25% (5/20) serotype 35B and 25% (5/20) a mixture of serotype 35B 127 
 o
n
 M
ay 29, 2018 by LIVERPO
O
L SCH O
F TRO
PICAL M
ED
http://jcm.asm.org/
D
ow
nloaded from
 
 6 
and 35D (Table 2). In all discrepant cases, we examined the cps locus sequences in an 128 
attempt to identify any gene loss and mixed wciG alleles. The cps locus region shared the 129 
same capsular genes with the serotype 35D reference (accession number KY084476), and the 130 
mutations in wciG were supported by at least 42X depth of reads (median: 80X; range: 42X 131 
to 143X) with 100% consistency. The discrepancy between phenotype and genotype could be 132 
due to 1) our inability to capture the serotype diversity in a clinical sample, since the bacterial 133 
culture subject to DNA extraction and Quellung testing were derived from a single colony 134 
that could be different between experiments; and 2) the possible inter-convertibility between 135 
serotype 35B and 35D during bacterial culture in vitro. In all five isolates which were both 136 
positive and negative to antisera fs35a under one microscope (Table 2), the mutations in 137 
wciG were either a 1-bp insertion or deletion that occurred after a 6- to 7-bp homopolymer, 138 
highlighting the possibility of inter-conversion between serotype 35B and 35D during DNA 139 
replication. Metagenomic analysis of clinical samples to snapshot the serotype diversity and 140 
investigation into the inter-convertibility of serotype 35B and 35D will potentially explain the 141 
discrepancy between the phenotypes and genotypes observed in this study. Considering the 142 
limitation of this study and our recent understanding of the genetic basis that differentiates 143 
serotype 35B and 35D (2, 6, 7), the non-silent mutations detected in wciG in this study 144 
strongly indicated the presence of serotype 35D pneumococci in the sample. Thus, the 23 in 145 
silico serotype 35D isolates were selected for further analysis.  146 
The mutation patterns of wciG among the in silico serotype 35D isolates were diverse. 147 
The wciG mutation patterns in the 23 serotype 35D isolates were different from the 6 148 
serotype 35D isolates reported previously (2, 5, 6). In total, there were twenty mutation 149 
patterns observed in 29 serotype 35D isolates from ten countries across four continents 150 
(Table 1). The most common naturally deficient WciG was due to 86_87insG, which 151 
occurred within a 6-bp homopolymeric stretch of guanine. It was first observed in an isolate 152 
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 7 
from Malawi in 2006, prior to the introduction of PCV7, and was also found in isolates from 153 
Senegal in 2011, South Africa and the USA in 2012, and New Zealand in 2015. Isolates with 154 
this mutation were sporadically distributed on the phylogenetic tree (Figure 1), suggesting 155 
that the mutations had arisen independently on multiple occasions. The convergence of 156 
mutations may imply that this site is a mutational hotspot.  157 
The majority of serotype 35D isolates belonged to the clonal complexes (CC)558 158 
(n=9), CC198 (n=6), and CC156 (n=5) that were primarily associated with serotype 35B (6, 159 
14, 15). The CC558 and CC156 lineages accounted for most of the increase in serotype 35B 160 
after the introduction of PCV13 in the USA (6), while CC198 is the major serotype 35B 161 
lineage in The Gambia (unpublished data). Based on a high-resolution SNP tree (Figure 1), 162 
serotype 35D pneumococci emerged among closely related serotype 35B isolates within 163 
different clusters. Together with the unrelated mutations observed in wciG, this strongly 164 
indicated that serotype 35B is the progenitor of serotype 35D.   165 
When compared with serotype 35B isolates, serotype 35D isolates were more likely to 166 
be recovered from sterile anatomical sites including cerebrospinal fluid (CSF; n=9), blood 167 
(n=8), lung aspirate (n=1), and joint aspirate (n=1) than among carriage isolates (n=4) [82.6% 168 
(19/23) vs 36.7% (154/420); p < 0.001 by Fisher’s exact test]. Based on a larger 169 
pneumococcal collection (n=3,333) randomly selected from the GPS project database, the 170 
empirical odds ratio (OR) for invasive disease due to serotype 35D is 11.58 (95% confidence 171 
interval 95% CI: 1.42-94.19), whereas the OR for serotype 35B is 0.61 (95% CI: 0.40-0.92). 172 
The increased invasive capacity in serotype 35D strain could be a result of evasion of the 173 
immune response targeting the capsule O-acetyl group. The observation in serotype 35B/35D 174 
coincides with a previous study on serotype 11A/11E, in which serotype 11E strains with a 175 
loss or reduced amount of acetylation in the capsule were found to be significantly associated 176 
with invasive pneumococcal disease (12, 16). The emergence of serotype 35D is likely 177 
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 8 
explained by Calix et al.‘s hypothesis (12) that pneumococcal capsule structure undergoes 178 
microevolution during progression from carriage to infection in response to divergent 179 
selection pressure in early mucosal colonization compared to later in a sterile site. This model 180 
of microevolution needs to be further investigated by characterizing the serotype dynamic 181 
over the development of invasive disease in vivo.  182 
Compared with the pre-PCV era, the prevalence of serotype 35D has not increased 183 
more than serotype 35B after the introduction of PCV13. (OR, 12.36; 95% CI: 1.5-100.6 v.s. 184 
OR, 3.54; 95% CI: 2.4-5.4; Table 3) in the randomly selected pneumococcal collection. A 185 
large proportion of 35D isolates (65.2%, 15/23) were collected after the rollout of PCV13. 186 
The post-PCV introduction isolates were all invasive isolates and were recovered in six 187 
countries (Cameroon, Malawi, New Zealand, South Africa, The Gambia, and the USA), 188 
highlighting that this invasive serotype is present in the residual pneumococcal population 189 
worldwide and could potentially be an example of serotype replacement. 190 
Among the 23 serotype 35D isolates, 87.0% (20/23) had at least one resistance 191 
determinant conferring resistance to commonly used antibiotics including penicillin (65.2%, 192 
15/23), erythromycin (30.4%, 7/23), cotrimoxazole (21.7%, 5/23), and tetracycline (4.3%, 193 
1/23). Similar to the previous studies on serotype 35B (6, 14), the penicillin-resistant isolates 194 
in this study were predominantly CC558 (60.0%, 9/15), followed by CC156 (35.7%, 5/15) 195 
and a singleton of ST373 (6.7%, 1/15).  Macrolide resistance mediated by mefA was 196 
significantly higher in serotype 35D isolates than in serotype 35B isolates (Table 4). Five of 197 
six serotype 35D isolates harboring mefA were from the USA, where macrolides are 198 
recommended for use as an empirical therapy for pneumonia in children (17-19); they all 199 
belonged to CC558, a major contributor to penicillin resistance in USA after introduction of 200 
PCV13 (14). Unlike the highly invasive but usually antibiotic susceptible serotype 1, 201 
pneumococci expressing serotype 35B (lower-invasive capsule) are more likely to be 202 
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 9 
commensal in the nasopharynx which could allow them to acquire antibiotic resistance 203 
determinants via horizontal gene transfer from other nasopharyngeal bacteria; a subsequent 204 
switch to serotype 35D (high-invasive capsule) would then transform the antibiotic resistant 205 
strain into a more virulent form.  206 
The limitation of this study is that the carriage and disease isolates included for  207 
calculating the invasiveness index were sampled in different cities in each country; all 208 
isolates included were collected between 2007 and 2015  from children aged < 2 years-old. 209 
Ideally, the carriage and disease isolates should be geography, time, and age-matched. In this 210 
instance, we calculated OR for invasiveness separately for each country: the ORs for invasive 211 
disease due to serotype 35B and 35D in The Gambia were 0.37 (95% CI: 0.09-1.56) and 20.3 212 
(95% CI: 2.10-196.42), respectively. The ORs could not be calculated for invasive disease as 213 
all serotype 35D isolates in South Africa and Malawi were from disease. The ORs for disease 214 
due to 35B in South Africa and Malawi were 0.68 (95% CI: 0.40-1.16) and 0.72 (95% CI: 215 
0.11 – 2.15), respectively. The ORs by country were consistent with the ORs calculated from 216 
the combined datasets of all three countries. Another limitation was that the effects of an in-217 
frame insertion of 15bp and the missense mutations in wciG on the protein function have not 218 
been evaluated. Removing these samples from all comparisons of serotype 35B and 35D did 219 
not alter the conclusions drawn from the statistical analyses. 220 
This study highlighted the global distribution of an invasive serotype 35D among 221 
young children in the post-PCV13 era and underlined the invasive potential conferred by the 222 
loss of O-acetylation in the pneumococcal capsule. 223 
 224 
MATERIALS AND METHODS 225 
 We retrospectively determined serotypes of 21,980 assembled pneumococcal 226 
genomes from the GPS project (n=16,575, May 2017, http://www.pneumogen.net/gps/) and a 227 
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 10 
compiled dataset (n=5,405) by Van Tonder et al. (13). DNA extraction was performed on a 228 
pure overnight culture derived from a single colony. Sequencing was performed on the 229 
Illumina HiSeq platform to produce paired-end reads of either 75 (2010-2011), 100 (2013-230 
2014) or 125 base pairs (2015-2016) in length. In silico serotype was determined using the 231 
whole genome sequence (WGS) based serotyping method PneumoCaT (20). As the current 232 
version of PneumoCaT does not distinguish serotype 35D from serotype 35B, all samples 233 
that were initially typed as serotype 35B were included in this study. To differentiate these 234 
two serotypes, nucleotide sequences of wciG were extracted from the assembled genomes 235 
and aligned to a reference sequence of 35B wciG (accession number KX021817) described 236 
by Geno et al. using CLUSTALW (2, 21). Mutations such as nonsense and frameshift 237 
mutations that led to pre-mature stop codon and in-frame insertion/deletions in wciG were 238 
predicted to reduce the function or a complete loss of function of the WciG protein. Isolates 239 
with these mutations were in silico typed as serotype 35D and their phenotypic serotype were 240 
determined by the Quellung reaction tested on an overnight culture derived from a single 241 
colony (22). Phylogenetic analysis was performed on all serotype 35B and 35D isolates by 242 
constructing a maximum likelihood tree using RAxML v.8.2.X (23) based on single 243 
nucleotide polymorphic sites (SNPs) extracted from a core gene alignment with Roary v.3.6.1 244 
(24). An empirical odds ratio for invasive disease due to serotype 35B and 35D was 245 
calculated based on a pneumococcal collection of 3,333 randomly selected carriage (n=1,260) 246 
and disease (n=2,073) isolates from children aged < 2 years-old, collected during the pre-247 
PCV (n=1,691), post-PCV7 (n=678), and post-PCV13 (n=964) eras using a previously 248 
described method (25). For each country, the random selection was carried out from a 249 
collection of disease isolates collected via laboratory-based surveillance and carriage isolates 250 
via cohort-studies using the following criteria: 50% isolates represented pre-PCV period (≤1 251 
year before) and 50% post-PCV period (≥2 years after primary, ≥1 after subsequent PCVs). 252 
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The randomly selected collection in this study included 67 different serotypes plus non-253 
typeable pneumococci. They were collected in South Africa (carriage n=721, disease 254 
n=1,047), Malawi (carriage n=336, disease n=60), and The Gambia (carriage n=1,016, 255 
disease n=153). Isolates from other locations in the GPS dataset were either not randomly 256 
selected, or consisted of only disease or carriage isolates and thus could not be used to 257 
calculate odds ratios. Susceptibility to chloramphenicol, cotrimoxazole, erythromycin, 258 
penicillin, and tetracycline were predicted by the identification of resistant determinants in 259 
the assembled genomes using previously described pipelines (26-28). The epidemiological 260 
and phylogenetic data can be interactively visualized and analyzed online using the 261 
Microreact tool at https://microreact.org/project/GPS_serotype_35B_35D 262 
 263 
Figure 1 Maximum likelihood phylogenetic tree was constructed using 56,848 SNPs 264 
extracted from a 1.02-Mb codon alignment of 1,141 core genes from 444 serotype 35B and 265 
35D S. pneumoniae isolates. The tree is colored according to the geographic location of each 266 
samples’ isolation. This analysis used an unrelated non-typeable isolate as the outgroup on 267 
which to root the tree. Clonal complex (CC) and mutations in wciG are shown to the right of 268 
the tree. Singleton sequence types and minor CCs with <5 isolates in this study are indicated 269 
in pink and grey, respectively. 270 
 271 
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 1 
Table 1. Genetic diversity of inactivating mutations in wciG of 29 serotype 35D S. pneumoniae isolates from the Global Pneumococcal 
Sequencing (GPS) project (n=23) and previous studies (n=6) 
wciG nucleotide mutation  n 
Clonal Complex/ 
Sequence Type  
Geographical location of 
isolation Year of isolation Site of isolation Ref. 
Frameshift mutation (n=18) a       
86_87insG 6 
CC156 (n=2), 
CC558 (n=2), 
CC198 (n=1),  
CC9813 (n=1) 
Malawi (n=2), New 
Zealand (n=1), Senegal 
(n=1), South Africa 
(n=1), USA (n=1) 
2006 (n=1), 2011 (n=1), 
2012 (n=2), 2015 (n=2) 
CSF (n=3), blood 
(n=2), joint pus 
(n=1) 
GPS 
914_929del_16bp 2 CC558  South Africa, USA 2012 (n=1), 2013 (n=1) 
CSF (n=1), blood 
(n=1) GPS 
162_163insT 2 CC558 USA 2004 (n=1), 2007 (n=1) 
Nasopharynx 
(n=2) GPSd 
92_93insC 1 CC198  The Gambia 2013  Blood  GPS 
705_706insT 1 CC156 Malawi 2015 CSF  GPS 
86delG 1 CC156 Cameroon 2012 CSF  GPS 
312delA 1 CC198 The Gambia 2009 Nasopharynx  GPS 
382_385_del_4bp 1 CC9813 South Africa 2012 CSF  GPS 
306_307insA 1 CC198 Australia 2016 unknown (5) 
36delA 1 CC558 Australia 2015 unknown (5) 
663_696del_34bp 1 CC452 Australia 2016 unknown (5) 
     
 
 
In-frame deletion/insertion (n=3)      
792_968del_177bpb 1 CC156 USA 2015 Blood (n=2) (6) 
755_808del_54bpb 1 CC558 Australia 2016 unknown (5) 
523_524ins_15bp 1 CC558 USA 2009 Blood GPS 
       
Nonsense mutation (n=7)       
C220T  2 CC156, ST373 Nepal, South Africa 2013 (n=1), 2014 (n=1) CSF (n=1), GPS 
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 2 
nasopharynx 
(n=1) 
T732G 2 CC198 The Gambia 2014 (n=2) 
CSF (n=1), blood 
(n=1) GPS 
C104A 1 CC558 USA 2012 Blood  GPS 
C323A 1 CC558 USA 2012 Blood  GPS 
T434G 1 CC198 The Gambia 2009 Lung aspirate  GPS 
       
Missense mutation (n=1)       
G533A, G679Ac 1 unknown USA unknown unknown (2) 
aAll frameshift mutations resulted in pre-mature stop codon. 
bThe in-frame deletion rendered the WciG, an acetyltransferase, non-functional. It was evidenced by the serological profiles reported by 
Chochua et al. (6) and Staples et al. (5)  
cThe resulting amino acid changes were R178K and A227T. The substitution led to a non-functional WciG, confirmed by serological test and 
NMR spectroscopic analysis 
dThese two isolates were reported in a previous study by Croucher et al. (29) and in silico serotype was updated as serotype 35D in this study. 
CSF, cerebrospinal fluid 
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 3 
Table 2. Serological profiles of 29 serotype 35D S. pneumoniae isolates from the Global Pneumococcal Sequencing (GPS) project (n=23) and 
previous studies (n=6) tested by the Quellung reactions 
Strain name Country CC Year wciG mutation P
oo
l G
 
Ty
pe
 2
9 
Ty
pe
 4
2 
G
ro
up
 3
5 
fs
35
a 
fs
35
b 
fs
35
c 
fs
29
b 
fs
42
a 
Phenotypic 
serotype Ref. 
3431-06 USA N/A N/A G533A, G679A + N N - - - + + - 35D (2) 
16S471 Australia CC198 2016 306_307insA + + + + - - + + - 35D (5) 
SAMDU-00005305 Australia CC558 2015 36delA + + + + - - + + - 35D (5) 
16S49 Australia CC452 2016 663_696del_34bp + + + + - - + + - 35D (5) 
16S35 Australia CC558 2016 755_808del_54bp + + + + - - + + - 35D (5) 
20152877 USA CC156 2015 792_968del_177bp + N N + - - + + - 35D (6) 
CH2075 USA CC558 2007 162_163insT + + - + + - + + - 35B GPSe 
3025 USA CC558 2004 162_163insT + + - + + - + + - 35B GPSe 
GPS_US_2010209945_
R1 USA CC558 2009 523_524ins_15bp + + - + + - + + - 35B GPS 
GPS_GM_1130 The Gambia CC198 2014 T731G (L244*) + + - + + - + + - 35B GPS 
GPS_GM_1148 The Gambia CC198 2014 T731G (L244*) + + - + + - + + - 35B GPS 
GPS_ZA_2370 
South 
Africa CC9813 2012 382_385delATAT + + + + - - + + - 35D GPS 
GPS_ZA_2636 
South 
Africa CC558 2013 914_929del_16bp + + + +b - - + + - 35D GPS 
2012215593 USA CC558 2012 914_929del_16bp + + - - - - + + - 35D GPS 
2012215608 USA CC558 2012 C104A (S35*) + + - - - - + + - 35D GPS 
GPS_ZA_2559 
South 
Africa CC156 2013 C220T (Q74*) + + + + - - + + - 35D GPS 
GPS_NP_7242 Nepal Singletond 2014 C220T (Q74*) + + N + - - + + - 35D GPS 
2012220613 USA CC558 2012 C323A (S108*) + + - - - - + + - 35D GPS 
2013208723 USA CC558 2012 86_87insG + + - - - - + + - 35D GPS 
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 4 
a
N, data not available 
bUnder the microscope, cells that were derived from a single-colony overnight culture showed both positive and negative to the antisera tested. 
cThis isolate was tested in two different laboratories and exhibit both positive to antisera fs35a in one laboratory and negative in another.  
dIsolate GPS_NP_7242 belong to ST373. A singleton that does not belong to any clonal complex. 
eThese two isolates were reported in a previous study by Croucher et al. (29) and in silico serotype was updated as serotype 35D in this study. 
GPS_MW_D38253_R1 Malawi CC156 2006 86_87insG + + - - - - + + - 35D GPS 
GPS_MW_BKR609 Malawi CC156 2015 86_87insG + + - - - - + + - 35D GPS 
PI0167 Senegal CC198 2011 86_87insG + + - + +b - + + - 35B/D GPS 
GPS_NZ_15SP0720 
New 
Zealand CC558 2013 86_87insG + + N + +c - + + - 35B/D GPS 
GPS_ZA_2487 
South 
Africa CC9813 2012 86_87insG + + + + +b - + + - 35B/D GPS 
GPS_MW_BKR5WC Malawi CC156 2015 705_706insT + + - +b +b - + + - 35B/D GPS 
PI0258 Cameroon CC156 2012 86delG + + - + +b - + + - 35B/D GPS 
GPS_GM_0282 The Gambia CC198 2013 92_93insC N N N N N N N N N N GPS 
GPS_GM_0600 The Gambia CC198 2009 312delA N N N Na N N N N N N GPS 
GPS_GM_0320 The Gambia CC198 2009 T434G (L145*) N N N N N N N N N N GPS 
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Table 3. The prevalence of serotype 35B and 35D S. pneumoniae from South Africa 
(n=1768), The Gambia (n=1169) and Malawi (n=396) in each vaccine period  
 No. of isolates (%) 
Odds ratio 
(95% confidence interval) 
Vaccine perioda serotype 35B serotype 35D serotype 35B serotype 35D 
Pre-PCV 
(n=1691) 36 (2.12) 1 (0.06) baseline baseline 
Post-PCV7 
(n=678) 12 (1.77) 0 
0.83 
(0.4 to 1.6) - 
Post-PCV13 
(n=964) 69 (7.16) 7 (0.73) 
3.54 
(2.4 to 5.4)* 
12.36 
(1.5 to 100.6)* 
aBased on the year of PCV introduction, we grouped each year of collection into three 
categories: pre-PCV period (years when no conjugated vaccine was used and the year of 
PCV7 introduction); Post-PCV7 (the second year of PCV7 introduction until the year when a 
higher-valent PCV was introduced); Post-PCV13 (the second year of PCV13 introduction 
until the end of the study year). PCV7 was introduced in South Africa and The Gambia in 
2009; PCV13 was introduced in South Africa, The Gambia, and Malawi in 2011. 
*p value < 0.05 
 
Table 4. Antimicrobial resistant determinants in serotype 35B and 35D S. pneumoniae 
isolates from the Global Pneumococcal Sequencing (GPS) project  
Antibiotic resistance 
determinants 
No. of isolates (%)  
serotype 35B (n=421) serotype 35D (n=23) P value 
ermB 3 (0.7) 1 (4.3) 0.192 
mefA 32 (7.6) 6 (26.1) 0.009 
tetM 36 (8.6) 1 (4.3) 0.710 
folA I100L and folP 
insertion 140 (33.3) 5 (21.7) 0.361 
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